22nd Century Group, Inc. (XXII): Price and Financial Metrics

22nd Century Group, Inc. (XXII): $0.91

0.04 (-4.01%)

POWR Rating

Component Grades








Add XXII to Watchlist
Sign Up

Industry: Biotech




#332 of 359

in industry

XXII Price/Volume Stats

Current price $0.91 52-week high $21.75
Prev. close $0.95 52-week low $0.91
Day low $0.91 Volume 229,900
Day high $0.99 Avg. volume 593,196
50-day MA $2.15 Dividend yield N/A
200-day MA $9.01 Market Cap 19.22M

XXII Stock Price Chart Interactive Chart >


  • Momentum is the dimension where XXII ranks best; there it ranks ahead of 75.31% of US stocks.
  • The strongest trend for XXII is in Value, which has been heading up over the past 177 days.
  • XXII's current lowest rank is in the Quality metric (where it is better than 0.33% of US stocks).

XXII Stock Summary

  • As for revenue growth, note that XXII's revenue has grown 113.72% over the past 12 months; that beats the revenue growth of 95.36% of US companies in our set.
  • In terms of volatility of its share price, XXII is more volatile than 96.27% of stocks we're observing.
  • 22ND CENTURY GROUP INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -232.06%, greater than the shareholder yield of just 2.7% of stocks in our set.
  • Stocks that are quantitatively similar to XXII, based on their financial statements, market capitalization, and price volatility, are VEEE, AYTU, XERS, XGN, and CREX.
  • XXII's SEC filings can be seen here. And to visit 22ND CENTURY GROUP INC's official web site, go to www.xxiicentury.com.

XXII Valuation Summary

  • In comparison to the median Consumer Defensive stock, XXII's EV/EBIT ratio is 102.89% lower, now standing at -0.5.
  • Over the past 154 months, XXII's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for XXII.

Stock Date P/S P/B P/E EV/EBIT
XXII 2023-09-22 0.3 0.3 -0.3 -0.5
XXII 2023-09-21 0.3 0.3 -0.3 -0.5
XXII 2023-09-20 0.3 0.3 -0.3 -0.5
XXII 2023-09-19 0.3 0.4 -0.3 -0.5
XXII 2023-09-18 0.3 0.4 -0.3 -0.5
XXII 2023-09-15 0.3 0.4 -0.4 -0.6

XXII Growth Metrics

    Its year over year price growth rate is now at -57.21%.
  • The 3 year net income to common stockholders growth rate now stands at -219.42%.
  • Its 3 year net cashflow from operations growth rate is now at -38.56%.
Over the past 33 months, XXII's revenue has gone up $25,032,470.

The table below shows XXII's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 50.865 -37.28 -47.483
2022-06-30 39.293 -30.321 -43.821
2022-03-31 33.187 -26.856 -36.497
2021-12-31 30.948 -22.839 -32.609
2021-09-30 30.296 -21.204 -25.048
2021-06-30 29.795 -16.418 -19.829

XXII's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • XXII has a Quality Grade of F, ranking ahead of 0.97% of graded US stocks.
  • XXII's asset turnover comes in at 0.448 -- ranking 5th of 5 Tobacco Products stocks.
  • MO, TPB, and PM are the stocks whose asset turnover ratios are most correlated with XXII.

The table below shows XXII's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.448 0.073 -0.387
2021-03-31 0.485 0.065 -0.480
2020-12-31 0.479 0.051 -0.435
2020-09-30 0.446 0.038 -0.388
2020-06-30 0.425 0.025 -0.494
2020-03-31 0.400 0.015 -0.537

XXII Price Target

For more insight on analysts targets of XXII, see our XXII price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $6.33 Average Broker Recommendation 1.5 (Moderate Buy)

22nd Century Group, Inc. (XXII) Company Bio

22nd Century Group, Inc., a plant biotechnology company, provides technology that allows for the level of nicotine and other nicotinic alkaloids in tobacco plants to be decreased or increased through genetic engineering and plant breeding. The company was founded in 1998 and is based in Clarence, New York.

XXII Latest News Stream

Event/Time News Detail
Loading, please wait...

XXII Latest Social Stream

Loading social stream, please wait...

View Full XXII Social Stream

Latest XXII News From Around the Web

Below are the latest news stories about 22ND CENTURY GROUP INC that investors may wish to consider to help them evaluate XXII as an investment opportunity.

22nd Century Group (XXII) Adds 1,200 Drug Store Locations Selling VLN® in Five States

First Drug Store Channel Retail Chain Begins VLN® Sales in September, Continues to Book Additional Launches for Rest of 2023BUFFALO, N.Y., Sept. 12, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading biotechnology company focused on utilizing advanced plant technologies to improve health and wellness with reduced nicotine tobacco, hemp/cannabis and hops, today announced its FDA authorized VLN® reduced nicotine content cigarettes designed specifically to promote tobacco h

Yahoo | September 12, 2023

Presenting on the Emerging Growth Conference on September 6 and 7 Register Now

MIAMI, Sept. 05, 2023 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 62nd Emerging Growth Conference on September 6 & 7, 2023. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the conference here. Submit Questions for any of the presenting com

Yahoo | September 5, 2023

22nd Century Group Initiates Strategic Alternatives Process for Its Tobacco Assets

BUFFALO, N.Y., Sept. 05, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ: XXII) (the “Company”) today announced that its Board of Directors, after consultation with its financial and legal advisors, has initiated a process to evaluate strategic alternatives with respect to the Company’s tobacco assets. The process will include consideration of a range of strategic, operational and financial transactions and alternatives, such as business combinations, asset sales, licensing agreements,

Yahoo | September 5, 2023

22nd Century Group, Inc. (NASDAQ:XXII) Analysts Just Slashed This Year's Revenue Estimates By 11%

The latest analyst coverage could presage a bad day for 22nd Century Group, Inc. ( NASDAQ:XXII ), with the analysts...

Yahoo | August 20, 2023

Adobe upgraded, BorgWarner downgraded: Wall Street's top analyst calls

Adobe upgraded, BorgWarner downgraded: Wall Street's top analyst calls

Yahoo | August 17, 2023

Read More 'XXII' Stories Here

XXII Price Returns

1-mo -48.59%
3-mo -82.64%
6-mo -92.11%
1-year -93.53%
3-year -90.34%
5-year -97.84%
YTD -93.41%
2022 -70.21%
2021 40.45%
2020 100.00%
2019 -55.82%
2018 -11.07%

Continue Researching XXII

Here are a few links from around the web to help you further your research on 22nd Century Group Inc's stock as an investment opportunity:

22nd Century Group Inc (XXII) Stock Price | Nasdaq
22nd Century Group Inc (XXII) Stock Quote, History and News - Yahoo Finance
22nd Century Group Inc (XXII) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!